Lorlatinib for advanced ALK and ROS1+non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.

Affiliation auteurs!!!! Error affiliation !!!!
TitreLorlatinib for advanced ALK and ROS1+non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.
Type de publicationJournal Article
Year of Publication2020
AuteursBaldacci S, Avrillon V, Besse B, Mennecier B, Duruisseaux M, Mazieres J, Descourt R, Doubre H, Dubray-Longeras P, Cadranel J, Moro-Sibilot D, Ricordel C, Galland-Girodet S, Monnet I, Otto J, Schneider S, Missy P, Morin F, Westeel V, Girard N
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume38
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X